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Abstract 
Purpose – This paper aims to assess the increasing challenges to governing the personal health 
information (PHI) essential for advancing artificial intelligence (AI) machine learning 
innovations in health care. Risks to privacy and justice/equity are discussed, along with potential 
solutions. 
Design/methodology/approach – This conceptual paper highlights the scale and scope of PHI 
data consumed by deep learning algorithms and their opacity as novel challenges to health data 
governance. Findings – This paper argues that these characteristics of machine learning will 
overwhelm existing data governance approaches such as privacy regulation and informed 
consent. Enhanced governance techniques and tools will be required to help preserve the 
autonomy and rights of individuals to control their PHI. Debate among all stakeholders and 
informed critique of how, and for whom, PHI-fueled health AI are developed and deployed are 
needed to channel these innovations in societally beneficial directions. Social implications – 
Health data may be used to address pressing societal concerns, such as operational and system-
level improvement, and innovations such as personalized medicine. This paper informs work 
seeking to harness these resources for societal good amidst many competing value claims and 
substantial risks for privacy and security. 
Originality/value – This is the first paper focusing on health data governance in relation to 
AI/machine learning. 
Keywords – Big data, Governance, Artificial intelligence, Deep learning, Personal health 
information 
1. Introduction and motivation 
Artificial intelligence (AI) technologies increasingly enable innovations from searching the 
internet to voice and facial recognition, smart appliances, and even to driverless cars. In the past, 
key limitations of AI have been the availability of sufficient data for training algorithms and the 
inability of AI systems to manage data in their natural form. Now, with omnipresent 
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digitalization of data about humans and their activities, deep learning[1] algorithms increasingly 
are able to take advantage of stockpiles of “big data” to enhance a learning model’s performance 
and extend the sophistication and reach of AI applications (Chen and Lin, 2014; Jordan and 
Mitchell, 2015). 
AI innovations are particularly promising in the domain of health and health-care services. From 
personalized health care tailored for each individual’s biology to improvements in health-care 
delivery systems, AI innovations are projected to revolutionize health-care outcomes for 
individuals and for health-care systems (Flores et al., 2013). Vital to these potential innovations 
are the vast stockpiles of individual-level health data needed for deep learning models. Now, 
personal health information (PHI)[2] data stores, such as notes from routine visits to the doctor, 
medical imaging, self-monitoring of steps, sleep and heartbeats, and DNA repositories, are 
rapidly accumulating, and will over time (given much-needed improvements in data quality and 
standardization), be applied to train deep learning algorithms in the growing array of AI health-
care applications (Miotto et al., 2017).  
The combination of AI, deep learning and digitized PHI data has been heralded as 
transformational for health care (Siwicki, 2017; Sullivan, 2017). Recognizing the potential of 
highly profitable health-care markets, information technology (IT) giants such as Alphabet/ 
Google, Microsoft, Apple, and IBM, along with dozens of technology startups, are partnering 
with health-care systems and investing in health-related mobile devices, health- care applications 
and AI technologies. In Europe and the USA alone, health-care AI markets have been valued in 
the hundreds of millions of Euros and are forecast to grow to over e7bn in Europe and e14bn in 
the USA by 2027 (PRNewswire, 2018). 
Compared to the projected benefits from health-care AI, much less consideration has yet been 
given to possible unintended or undesirable consequences of these developments for individuals 
and for society. Many questions remain unanswered and will grow in importance. For instance, 
who will pay the costs and who will reap the benefits of health- related AI innovations? Will 
costly advances in personalized medicine be limited to wealthy nations (as was seen with AIDS 
drugs), or even to the wealthy few in these nations? Will PHI be linked to innocuous trace 
activity data through AI/machine learning methods and used to limit an individual’s access to 
social and economic opportunities, based on that individual’s predicted health status? How can 
we best govern algorithms to reduce risk amidst complex systems with a high degree of 
uncertainty? (Saurwein et al., 2015). These are just a few of the ethical and societal issues than 
need to be surfaced and debated as governments, health systems, and importantly, global IT 
firms aggressively pursue AI ventures in health care. 
In this paper, we draw on Giddens’s metaphor of the relentless scientific progress of modernity 
as a juggernaut – a powerful and dangerous force that is difficult to steer (Giddens, 1990, p. 151) 
– to focus attention on one critical aspect of what may be a developing health-care AI 
juggernaut: the challenges of governing the PHI data that are essential to advancing AI and 
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machine learning in health care. PHI data governance addresses privacy, security, ownership and 
use and reuse of health data as well as the underlying values and interests that shape data 
governance structures (Winter and Davidson, 2017). We highlight two attributes of AI deep 
learning that, while not unique to the health-care setting, pose significant and novel challenges to 
PHI data governance: the scale and scope of data consumed by deep learning algorithms, and the 
opacity of algorithms in regards to how data are utilized and new data or results are produced. 
We then argue that existing data governance structures will not be sufficient to address the 
radical uses and reuse of PHI data brought about by deep learning technologies, focusing on two 
common governance approaches: preemptive privacy regulation and informed consent. We 
conclude by considering new approaches to data governance required to enable accessibility of 
PHI for AI innovations but also to preserve the autonomy and rights of individuals to control 
their PHI and to channel the power of AI and machine learning for health-care transformation in 
societally beneficial directions. 
 
1.1 Fueling the artificial intelligence health-care juggernaut 
PHI data governance is concerned with balancing individual privacy, authorized access to PHI 
data, and data security with the benefits of utilizing data for health system improvement and 
innovation (Hripcsak et al., 2014; Rosenbaum, 2010). Government regulators and researchers 
have advocated for health data sharing and for standards and infrastructures to enable health data 
interoperability (Blumenthal, 2010; Hripcsak et al., 2014; Rosenbaum, 2010). A tacit assumption 
is that wide-scale sharing of health data will necessarily serve the public good. Given the 
economic value that may be exploited from PHI data to serve corporate interests, such 
assumptions are not fully warranted (Harper, 2013; Rosenbaum, 2010). Now, with AI and 
machine learning at the frontier of health system transformation, novel, and heightened, 
challenges to PHI data governance must be addressed. 
  
2. The complexity of personal health information data and challenges of data 
governance 
The term PHI data relates to a variety of data domains that contain personally identifying (or 
potentially identifying) characteristics: medical history data; clinical data collected in EHR 
systems of hospitals, physicians, and laboratories; pharmacy prescription data; patient- generated 
health data from medical devices (such as a glucose monitor) or general purpose activity tracker 
(such as a Fitbit step tracking device); and medical expense claims data. Other PHI data domains 
are created by analyzing data not directly connected to health status, but health status can be 
inferred analytically. These data can be characterized as consumer-generated health data, for 
instance trace data from internet search activities, credit card purchases and online shopping, or 
geospatial/location data. 
Post‐print 
 
Winter, J. S., & Davidson, E. (2019). “Governance of artificial intelligence and personal health information.” Digital 
Policy, Regulation and Governance (DPRG), 21(3), 280-290. Special issue on “Artificial Intelligence: Beyond the 
hype?”  doi:10.1108/DPRG-08-2018-0048 
 
These various PHI data are governed by an equally wide variety of stakeholders from health-care 
providers to retailers to IT firms. Data governance has been defined as “a system of decision 
rights and accountabilities for information-related processes, executed according to agreed-upon 
models which describe who can take what actions with what information, and when, under what 
circumstances, using what methods” (Data Governance Institute, n.d., para. 2). In the 
information systems field, data governance refers primarily to management of organizational 
data by that organization (Khatri and Brown, 2010), but new forms of inter-organizational data 
governance are also developing to take advantage of “big data” and advancing analytics 
capabilities such as AI, for instance data collaboratives in fields such as genetics research and 
clinical trials (Perkmann  and  Schildt, 2015;  Susha  et al., 2017) and distributed research 
networks (DRNs) (Holmes et al., 2014). 
Effective health data governance remains an elusive goal for myriad reasons, and with ever 
increasing digital stockpiles of digitized PHI, a growing challenge (Hripcsak, 2014; Rosenbaum, 
2010). First, digitized health data are created in health IT (HIT) systems spread across a variety 
of collaborative and competing organizations, including hospitals, physician practices, nursing 
homes, third-party payers (insurers) including state and federal governments, pharmacies, testing 
laboratories, and increasingly, by IT vendors that provide HIT systems. This results in the lack of 
data standardization and interoperability that currently presents substantive barriers to PHI data 
sharing and data use, including use in advanced analytics and AI applications. Second, 
regulations intended to limit the  disclosure of personally-identifiable health data (such as 
HIPAA in the USA or GDPR in the European Union) have limited the flow and increased costs 
to researchers to access PHI data for societally sanctioned purposes (Lane and Schur, 2010). 
Third, with rising popularity of health monitoring devices and applications, patient-generated 
health data (PGHD) resources are developing outside of clinical settings and health data 
regulatory oversight (Deering et al., 2013). Individuals create PHI through wearable activity 
monitors or share their PHI with commercial firms (e.g. for genetic profiling) or patient support 
groups (Tempini, 2017). In many instances, these data are not covered by health privacy 
protection legislation as consumers, often unwittingly, grant to the commercial firm (e.g. Fitbit, 
Apple, 23andMe) governance rights for these data. 
There are substantive challenges for governing PHI data so as to balance the varied interests of 
diverse stakeholders – individuals, health-care practitioners, regulators, third- party health-care 
funders, health-care innovators including IT firms, and so on. Despite existing issues, there are 
nonetheless relentless societal and regulatory pressures to make PHI data even more available for 
research and innovation (Siwicki, 2017; Sullivan, 2017) so as to realize the transformations in 
health and health services projected from these developments. The possibilities of AI and deep 
learning both increase these pressures and create even more challenges for PHI data governance. 
Next, we highlight two such challenges: the scale and scope of PHI utilized by these advances 
and the opacity of the AI algorithms. 
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2.1 Scale and scope of personal health information data aggregation and use 
Deep learning algorithms rely on massive data sets to train and improve AI models (Chen and 
Lin, 2014; Jordan and Mitchell, 2015). The growing stockpiles of digitized PHI data available 
through research and commercial arrangements provide essential fuel for deep learning 
innovation in health care (Murdoch and Detsky, 2013). PHI data include a broad array of data 
from routine transactions to novel data types such as Internet-of-Things medical devices 
embedded in clinical settings, daily life and even in human bodies (Deering et al., 2013). In 
many countries, data on health services encounters (e.g. doctor visits, hospital care) are captured 
in electronic health record systems. Transactions such as filling a prescription or purchasing an 
over-the-counter medication are digitally recorded (e.g. by retail pharmacies). Search engines 
such as Google capture individuals’ search histories for health-related information, while social 
media platforms collect and correlate data on health-related interactions (Eichler et al., 2016; 
Sarasohn-Kahn, 2014). Although these PHI data are scattered across data platforms today, in the 
future, as deep learning algorithms become more sophisticated, these various data sources are 
likely to be compiled, linked, made available for reuse (possibly sold between private brokers) 
and then used to develop profiles of individuals’ behaviors and for predictive health models 
(Bates et al., 2014; Cohen et al., 2014; Siegel, 2016). 
That is, the scale and scope of personally identifiable health-related data that will be available in 
the near future for AI and deep learning have increased dramatically in the last decade. 
Moreover, trace data that are not specifically related to health are also collected and mined to 
link everyday activities (Web browsing, household activities harvested through devices such as 
Alexa or Google Home, television viewing habits, supermarket purchases) to health status or 
behaviors (Mai, 2016). These trace data, which are not protected by health data privacy 
regulations or even acknowledged explicitly as health- related, “can be combined with personal 
information from other sources–including health- care providers and drug companies–raising 
such potential harms as discriminatory profiling, manipulative marketing, and data breaches” 
(Montgomery et al., 2018, p. 42). 
Deep learning algorithms also create a whole new category of predictive health data about 
individual and group behaviors. As Kitchin and Lauriault (2016, p. 12) note, “a person’s data 
shadow does more than follow them; it precedes them” when used for predictive profiling and 
social sorting into categories. For instance, behavioral data from web searches or biometric data 
from fitness trackers can be linked to other data sources to create profiles of individuals. These 
models of probabilities, as well as a wide variety of metadata and trace data about daily 
activities, can be used to categorize individuals, make predictions about their behavior, and then 
to prioritize the use of health-care resources based on these profiles (Cohen et al., 2014), without 
the profiled individual’s consent or awareness. 
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2.2 Opacity of personal health information data in artificial intelligence algorithms 
A lack of transparency in corporate-public data sharing arrangements in AI partnerships, and the 
inherent opacity of deep learning algorithms raise questions about the feasibility of effective PHI 
data governance. For instance, Xiao et al. (2018), note that “to bring deep models built from 
EHR [electronic health records] data into real use, users often need to understand the 
mechanisms by which models operate. Such a level of model transparency is still challenging to 
achieve” (p. 1425). Deep learning is a “black box” (Pasquale, 2015), with its inner workings 
obscured by the opacity and complexity of algorithms. Despite efforts towards interpretable 
machine learning and AI, and “explainable AI”, which use mathematics to simplify black boxes, 
human understanding and real-world application of these abstractions is still problematic (Abdul 
et al., 2017). Burrell (2016) observes that this opacity is at the center of growing concerns about 
algorithms by legal scholars and social scientists. In some cases, opacity may be an “intentional 
corporate or institutional self-protection and concealment” (Burrell, 2016, pp. 1-2), particularly 
to protect corporate intellectual property and competitive advantage. In others, those examining 
an AI system may lack the specialized coding skills to understand its processes. A third type of 
opacity, characteristic of deep learning, relates to the scale and complexity of machine learning, 
and thus to humans’ difficulty understanding an algorithm in action as it reads real-time data and 
adapts. Burrell (2016, p. 5) comments, “Though a machine learning algorithm can be 
implemented simply in such a way that its logic is almost fully comprehensible, in practice, such 
an instance is unlikely to be particularly useful”. 
Thus, increasingly, opacity is inherent in the process of developing and deploying AI deep 
learning algorithms across many data domains and applications (Faraj et al., 2018). In the health-
care domain, opacity is problematic not only for monitoring what PHI data are used, but also for 
understanding the purposes and outcomes of data use, for instance the possibility of 
discriminatory profiling. Barocas and Selbst (2016) argue that discrimination is often an 
“unintentional emergent property of the algorithm’s use rather than a conscious choice by its 
programmers, [but] it can be unusually hard to identify the source of the problem or to explain it 
to a court” (Barocas and Selbst, 2016, p. 1). Burrell’s latter category (human ability to 
understand the algorithm’s operation) makes specifying and monitoring PHI data governance 
particularly problematic. 
 
3. Controlling the health-care artificial intelligence juggernaut 
Given the sensitivity of personal health data and existing legal and regulatory protections, PHI 
data governance approaches are more mature than in many socioeconomic sectors (Hripcsak et 
Post‐print 
 
Winter, J. S., & Davidson, E. (2019). “Governance of artificial intelligence and personal health information.” Digital 
Policy, Regulation and Governance (DPRG), 21(3), 280-290. Special issue on “Artificial Intelligence: Beyond the 
hype?”  doi:10.1108/DPRG-08-2018-0048 
 
al., 2014; Rosenbaum, 2010). However, existing PHI data governance structures are unlikely to 
be sufficient to control the combined momentum of AI, deep learning and aggregation of PHI, or 
thus to help channel developments along societally beneficial and equitable directions. 
 
3.1 Preemptive health data regulation 
Data protections vary from country to country, but even the most stringent regulations may prove 
to be ineffective to manage the flow of PHI data into AI ventures and thus into the purview of 
varied public, private, and for-profit stakeholders. Effective regulation depends on clear and 
comprehensive articulation of regulatory requirements as well as the regulating authority’s 
ability to evaluate and monitor compliance (Jordan and Mitchell, 2015). Good- faith compliance 
with regulations is also important, as the harm resulting from violations may be difficult to detect 
and to repair. 
The European Union is focusing on digitization of health care, fostering standardization of 
electronic health records and developing data analytics and AI to enhance innovation and 
improve care (European Commission, 2018). The recent European Union General Data 
Protection Regulation (GDPR, European Parliament and Council of the European Union, 2017) 
grants individuals multiple rights (e.g. the “Non-Discrimination Right”, the “Right to 
Explanation”, and the “Right to Be Forgotten”), and health data are afforded a special category 
requiring higher protection. The GDPR is currently the strongest data protection regime in the 
world; however, it may be inadequate to address the tradeoffs between individual privacy and 
autonomy and the promised individual, societal and economic benefits of health-care AI 
ventures. For example, the scale and scope of PHI data necessary for training deep learning 
algorithms, and the opacity of how these algorithms operate, make accurate and comprehensive 
articulation of data use regulations and the monitoring of compliance with PHI data regulations 
very difficult (Kuner et al., 2017). For instance, Article 22(1) of the GDPR relates to “personal 
data used for automated decisions” and specifies that data should only be gathered for “specified, 
explicit, and legitimate purposes, and subsequent processing that is incompatible with those 
purposes is not permitted” (Kuner et al., 2017, p. 3). However, as large amounts of PHI data 
must be processed to train deep learning models (Xiao et al., 2018), developing these models will 
likely rely on the reuse of a variety of PHI data that are collected for other purposes (such as 
providing a health-care service or payment for services). 
Is a deep learning model developed to predict disease progression and health-care resource 
consumption compatible with those purposes? Because of the scale and scope of PHI data 
needed to effectively train models and the dynamic nature of data use in deep learning, “it may 
be difficult to reconcile such dynamic processes with purposes that are specified narrowly in 
advance” (Kuner et al., 2017, p. 3). The opacity of algorithmic processes and the conclusions 
generated, such as predictive profiles, make monitoring compliance difficult and may also mask 
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potential harm from regulatory oversight, particularly in areas not directly related to health care 
(e.g. health-related discrimination in employment or access to financial services like credit or 
insurance). 
The temptation for organizations that control PHI to interpret broadly, or even disregard, PHI 
data regulations in the face of the much-heralded potential of AI innovation was evident in a 
recent case in the UK Despite the UK’s stringent health data privacy laws, in 2015, a National 
Health Services (NHS) hospital system (Royal Free) provided five years of medical data on 1.6 
million of its patients to a commercial, for-profit AI venture (Alphabet DeepMind Health). Data 
were provided in an open-ended agreement intended to help DeepMind develop health-care AI 
applications that Royal Free patients might later benefit from (Hawkes, 2016). In 2017, the UK 
Information Commissioner’s Office (ICO) ruled that the DMH-Royal Free data sharing 
agreement had not complied with existing data protection laws. In response to regulatory 
concerns, Royal Free and DeepMind Health subsequently enhanced their self-regulation PHI 
governance procedures, but they also extended their data sharing agreement for another five 
years (Lomas, 2017), an indication of the strong lure of AI innovation for health service 
providers and IT firms. 
 
3.2 Informed consent 
As deep learning broadens the scope and scale of data used in health-care analytics, the concept 
of informed consent is itself challenged. For instance, a patient may authorize sharing of her 
health data to facilitate delivery of health-care services (to herself) and of payments from third-
party payers. Her PHI then falls under the control of various organizations, which may later 
share her data for health research or use in system-wide efficiency analytics, and even for sale 
(within regulatory limitations). The promises of health system transformation through AI and 
machine learning increase the appeal of such data sharing arrangements, as was seen in the NHS 
Royal Free-DeepMind Health case. Royal Free administrators claimed that explicit patient 
consent for data sharing was not required and could be assumed, because (some of the) PHI data 
were to be used for direct care of (some) patients (Hawkes, 2016). 
A regulatory workaround to grant access to PHI data without an individual’s informed consent is 
to de-identify patient data. However, (re)identified data are more valuable for AI deep learning to 
recognize and exploit associations among data sources. Re-identification of PHI data subverts 
regulatory intent but it is not difficult technically (El Emam et al., 2011; Rothstein, 2010). For 
example, Facebook founder Mark Zuckerberg revealed in testimony before the US Congress in 
April 2018 that his company collects some health data about individuals. That same month, it 
was revealed that Facebook had initiated a project to gain anonymized patient data to “match 
hospitals’ patient data on diagnoses and prescription information with Facebook so the company 
could combine that data with its own to construct digital profiles of patients [.. .] Facebook’s 
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stated intent was never to leave the data anonymized. But requesting the hospitals’ data in that 
form would allow Facebook to sidestep the issue of obtaining patients’ consent, as required by 
federal law” (Ostherr, 2018, para. 5-6). This instance illustrates the economic value that 
commercial firms operating outside of the health-care setting, here a social media firm, are 
looking to harvest from PHI through advanced analytics and AI. This instance also illustrates 
how one’s data shadow from a variety of daily activities (e.g. Facebook postings) can be merged 
with ostensibly protected health data outside the boundaries of informed consent practices. 
Genomic data and their use in precision genomics provide another illustration of the limits of 
informed consent arising from the networked properties of PHI data. One individual’s DNA is 
part of a biological (and now informational) network that extends to ancestors, family members 
and relatives, and future descendants (Azencott, 2018). Speaking broadly of data privacy, boyd 
(2012) describes this as networked privacy: “What we share about ourselves tells heaps about 
other people” (boyd, 2012, p. 1). Precision genomics rely on a variety of data-intensive tests to 
understand variants in DNA sequences and their health implications, and thus on widespread 
sharing of a broad, varied scope of PHI including DNA (Aronson and Rehm, 2015). While 
medical records tend to focus on individual patients who may consent to the use of this data, one 
individual’s DNA may reveal sensitive personal information about others who have not 
consented to share it (or have even been born). Groups such as the Regulatory and Ethics 
Working Group of the Global Alliance for Genomics and Health have created frameworks for 
the responsible sharing of genomic data, as well as standards for obtaining consent. However, as 
with other forms of PHI, these “DNA networks” housed across multiple genomics repositories 
are also susceptible to (re) identification (Gymrek et al., 2013). 
 
3.3 Enhancing personal health information data governance structures 
We have argued that preemptive data use regulations will not be sufficient to address the scale 
and scope of PHI data utilization and the opacity of AI deep learning algorithms. Beyond 
governing the inputs of deep learning, heightened governance of the processes and uses (outputs) 
of deep learning will also be needed. For instance, in response to growing concerns about data 
ethics and negative social consequences, interdisciplinary scholars have begun to develop field 
experiments that detect discrimination arising from AI and big data analytics (Sandvig et al., 
2014). Ironically, deep learning methods can be applied to detect unintended or intentional 
societal effects from deep learning. This approach is echoed by the Royal Statistical Society’s 
(Royal Statistical Society, 2016) call for an inquiry about “methods that the public can use to 
hold algorithms to account” (Royal Statistical Society, 2016, p. 3). These “algorithmic audits” 
will initially be limited because of the opacity of AI algorithms and laws that protect proprietary 
systems and intellectual property. However, there is some promise in requiring auditability to be 
designed into systems so that that AI and deep learning systems create an audit trail explaining 
what data were accessed and how data were used. For example, Alphabet’s DeepMind Health AI 
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venture has designed a technical governance structure, the “Verifiable Data Audit”, which uses a 
technology similar to blockchain to provide a real-time audit and verification of PHI data access 
and use (DeepMind, 2017). DeepMind intends that this will make its use of PHI data more 
transparent to authorized reviewers. In this case, the novel technique is intended to govern the 
process of data analysis and predictive modeling. 
As current informed consent practices will not suffice to govern the scale and scope of PHI data 
utilized in AI deep learning ventures, more advanced sociotechnical solutions will be needed. 
Sharon (2016) argues that much research using big data sets challenges traditional understanding 
of informed consent because related risks cannot be forecast at the time of collection; thus, new 
models of open, broad and portable consent are being developed for research purposes. Beyond 
the ethical questions of using PHI in research is “the unavoidable question of who stands to 
benefit and in which way from research results” (Sharon, 2016, p. 568). Because AI algorithms 
themselves still belong to some human entity, the outputs and uses of outputs of deep learning 
methods could also become subject to regulation. Requirements might be voluntary in some 
cases and in others may require multilayered regulation to ensure compliance. Articulating such 
regulations will require personnel with sufficient training in deep learning methods to understand 
their consequences, as well as public debate about the compromises that allowing, or restricting, 
such innovations may entail (Singer, 2018). 
 
4. Concluding remarks 
Giddens (1990) termed circumstances in which the momentum to pursue scientific advancements 
crushes consideration of possible societal consequences as a juggernaut. In this essay, we have 
questioned whether growing trends towards (relatively) unfettered use of personal health data in 
machine learning will fuel a health AI juggernaut. The promises of health, health services, and 
health system transformation that might be possible through AI/ machine learning innovations 
are substantial and compelling. We argued that the scale and scope of PHI data consumed by 
deep learning models and the opacity of these algorithms will overwhelm current approaches to 
PHI data governance, in particular, preemptive data regulations and informed consent practices. 
To merely maintain some balance between individual rights and autonomy, and corporate 
interests in extracting value from PHI through AI, new data governance techniques and tools will 
be required. 
To mitigate high-consequence risks of the juggernaut, Giddens advocates for us to “envision 
alternative futures whose very propagation might help them be realized” (1990, p. 154). IS 
scholarship can inform, and thereby help actualize, more desirable futures by illuminating the 
diverse interests, values, and conflicts underlying technology developments (Chiasson et al., 
2018). As a small contribution to this larger program, our focus here has been on the 
aggregation, use, and reuse of PHI and other data for AI deep learning and the challenges to data 
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governance these innovations pose. Enhancing PHI data governance approaches is critically 
important, but this alone this will not control the health AI juggernaut. Questions of who benefits 
from, and who pays the price for, health AI developments remain. We will need to look beyond 
the glowing promises and allure of health and health-care systems “transformed” by AI to 
consider which stakeholder interests and values are (or will) be served by various AI ventures, 
and to debate whose interests and values should be served. As one example, intentional opacity 
of data sharing agreements and learning model operations that limit effective PHI data 
governance can lead to debates on whether health AI ventures should be governed by intellectual 
property rights of corporations or conducted within the public domain for the public good. 
Reasoned critique is required, as well as empirical study of developments and their 
consequences, to help ensure health AI will contribute to the broader public interest as well as to 
individual well-being in the future. 
 
Notes 
1. Machine learning, a subset of artificial intelligence, enables many functions of modern 
industrial societies – from searching the Web, voice and facial recognition, smart 
appliances, to driverless cars. A key limitation of traditional machine learning has been 
its inability to manage data in their natural form, requiring transformation of raw data 
into meaningful features (i.e. individual, measurable characteristics). Deep learning is a 
subset of machine learning that relies on massive amounts of raw data to enhance model 
performance. Deep learning is already widely applied across a range of domains, 
including healthcare. 
2. In the United States context, PHI refers to Protected Health Information or Personal 
Health Information. We broadly use the term PHI to refer to “personal health data”. 
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